Glioblastoma, Gliosarcoma
Conditions
Keywords
Glioblastoma, Gliosarcoma, Bevacizumab, Avastin, Erlotinib, Tarceva, Temozolomide, Temodar
Brief summary
This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately following a standard course of up-front radiotherapy and Temodar. All patients will receive Bevacizumab, Temodar and Tarceva. A total of 60 patients will be enrolled. Our hypothesis is that the combination of Bevacizumab plus Temodar and Tarceva will increase survival over that seen in historical controls who have newly diagnosed, non-progressive glioblastoma or gliosarcoma following radiotherapy plus Temodar and use Temodar alone.
Detailed description
Patients with newly diagnosed glioblastoma or gliosarcoma are treated with standard of care radiation and temozolomide, plus the addition of Bevacizumab and Tarceva. The dose of temozolomide, Bevacizumab and radiation are the same for all patients. Tarceva dose is based upon the use of enzyme inducing anti-epileptic agents. Tarceva is given daily; Bevacizumab is given every 2 weeks; radiation is for 6 weeks, and temozolomide is given daily during radiotherapy and then in the adjuvant setting, is given on a 5-day schedule every 28 days. Patients are followed for progression and survival. The measure of response is MR scanning every 2 months. Dose adjustments are based upon the specific toxicity of the agent in question which differs for each agent (Bevacizumab, temozolomide, or Tarceva). Patients are not randomized, but assigned to an arm based on use of anti-epileptic agents.
Interventions
DRUGBevacizumab
Patients are given 10 mg/kg IV Q2 weeks.
DRUGTarceva
Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
DRUGTemozolomide
Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
Sponsors
University of California, San Francisco
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologically proven, non-progressive glioblastoma multiforme (GBM) or gliosarcoma (GS) with stable disease immediately following XRT + TMZ. All patients will receive Bevacizumab plus Tarceva and TMZ. * Biopsy or resection must have been performed prior to RT + TMZ. * No chemotherapy is allowed prior to starting RT + TMZ, including Gliadel Wafers. * Patients will have started RT + TMZ prior to registration and study entry and are eligible as long as they do not have progressive disease and can start Bevacizumab + TMZ and Tarceva within 4 weeks after the completion of RT + TMZ. Patients MUST have been treated with at least 54 Gy radiotherapy (60 Gy recommended) and MUST have received Temodar concurrently with radiotherapy for eligibility for this study. * Patients may or may not have measurable or evaluable disease on contrast MR imaging. A post-radiotherapy MRI scan must document stable disease. * Patients must be \> 18 years old and with a life expectancy \> 12 weeks. * Patients must have a Karnofsky performance status of ≥ 70. * Patients must have adequate bone marrow function (WBC \> 3,000/µl, ANC \> 1,500/mm3, platelet count of \> 100,000/mm3, and hemoglobin \> 10 mg/dl), adequate liver function (SGOT and bilirubin \< 1.5 times ULN), and adequate renal function (creatinine \< 1.5 mg/dL) before starting therapy. These tests must be performed within 14 days prior to initial treatment.
Exclusion criteria
* Patients must not have evidence of recent hemorrhage on baseline MRI of the brain, with the following exceptions: presence of hemosiderin, resolving hemorrhage changes related to surgery, presence of punctuate hemorrhage in the tumor. * Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate this therapy or any disease that will obscure toxicity or dangerously alter drug metabolism. * Patients must not have proteinuria at screening as demonstrated by either * Urine protein: creatinine (UPC) ratio ³ 1.0 at screening OR * Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Patients must not have inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \> 100 mmHg) on antihypertensive medications. * Patients must not have any prior history of hypertensive crisis or hypertensive encephalopathy. * Patients must not have New York Heart Association Grade II or greater congestive heart failure (see Appendix E). * Patients must not have history of myocardial infarction or unstable angina within 12 months prior to study enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Approximately 6-24 months | Overall survival was defined from the date of diagnosis to date of death from any cause |
| Unexpected Toxicities During First 2 Cycles of Study Drug | Within 8 weeks of initiating study therapy | Unexpected severe study-related adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | Approximately 6 months to 1 year | Progression-free survival was defined from the date of diagnosis to the date that progressive disease was first observed on imaging, or the date at which nonreversible neurologic progression or permanently increased corticosteroid requirement, death from any cause, or early discontinuation of treatment. Imaging guidelines were used to evaluate progression: (i) 25% increase in the sum of products of all measurable lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline; (ii) clear worsening of any assessable disease; (iii) appearance of any new lesion/site; and (iv) clear clinical worsening or failure to return for evaluation as a result of death or deteriorating condition (unless clearly unrelated to this cancer). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Efficacy Group Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity | 59 |
| Safety Lead-in Group A safety lead-in group received bevacizumab and erlotinib added to TMZ after completion of radiation to rule out unexpected toxicity of the combination of drugs. | 15 |
| Total | 74 |
Baseline characteristics
| Characteristic | Efficacy Group | Safety Lead-in Group | Total |
|---|---|---|---|
| Age, Continuous | 54 years | 65 years | 58 years |
| Region of Enrollment United States | 59 participants | 15 participants | 74 participants |
| Sex: Female, Male Female | 29 Participants | 3 Participants | 32 Participants |
| Sex: Female, Male Male | 30 Participants | 12 Participants | 42 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 53 / 59 | 14 / 15 |
| serious Total, serious adverse events | 32 / 59 | 7 / 15 |
Outcome results
Primary
Overall Survival (OS)
Overall survival was defined from the date of diagnosis to date of death from any cause
Time frame: Approximately 6-24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Efficacy Group | Overall Survival (OS) | 19.8 months |
Primary
Unexpected Toxicities During First 2 Cycles of Study Drug
Unexpected severe study-related adverse events
Time frame: Within 8 weeks of initiating study therapy
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Efficacy Group | Unexpected Toxicities During First 2 Cycles of Study Drug | 0 Events |
Secondary
Progression-free Survival
Progression-free survival was defined from the date of diagnosis to the date that progressive disease was first observed on imaging, or the date at which nonreversible neurologic progression or permanently increased corticosteroid requirement, death from any cause, or early discontinuation of treatment. Imaging guidelines were used to evaluate progression: (i) 25% increase in the sum of products of all measurable lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline; (ii) clear worsening of any assessable disease; (iii) appearance of any new lesion/site; and (iv) clear clinical worsening or failure to return for evaluation as a result of death or deteriorating condition (unless clearly unrelated to this cancer).
Time frame: Approximately 6 months to 1 year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Efficacy Group | Progression-free Survival | 13.5 months |